Navigation Links
CardioDx Completes Validation Study of First-Of-Its-Kind Genomic Test for Coronary Artery Disease
Date:8/25/2009

PALO ALTO, Calif., Aug. 25 /PRNewswire/ -- CardioDx, a cardiovascular genomic diagnostics company, announced today that the company has successfully completed its multicenter validation study for Corus(TM) CAD, the first and only gene expression test to quantify the likelihood of obstructive(1) coronary artery disease (CAD) in patients with stable chest pain. The company expects to present results of the study by the end of 2009, and will publish the results in 2010.

Following completion of the validation study, CardioDx has made Corus CAD available in nine states initially, with broader availability expected in 2010. The test is now available in Kentucky, Maryland, Illinois, Washington, Wisconsin, Minnesota, North Carolina, Texas and Arizona. Patient samples are processed in Palo Alto at CardioDx's CLIA-certified laboratory.

"Completing the validation study for Corus CAD marks a major milestone for CardioDx," said David Levison, chief executive officer of CardioDx. "Our focus now turns to further developing the clinical and economic evidence needed to increase patient access to the unique benefits of Corus CAD."

Currently, the presence of obstructive CAD in patients with stable chest pain is most often evaluated through functional and/or anatomical assessment of the heart and its vessels, including stress echocardiography, myocardial perfusion imaging, and computed tomography angiography. However, despite advances in imaging technology, these techniques can be subjective and challenging for cardiologists, because of variation in presenting symptoms and each patient's unique disease characteristics. Corus CAD provides unique genomic information about an individual's disease processes at the molecular and cellular levels. When this information is combined with standard clinical assessments, physicians obtain a more complete picture of their patient's disease and can bett
'/>"/>

SOURCE CardioDx
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
6. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
7. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
8. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
9. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
10. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
11. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... , Feb. 27, 2015  Organovo Holdings, ... company focused on delivering breakthrough 3D bioprinting technology, ... and Chief Executive Officer, will present live at ... invite you to join us for this Company ... updates on our commercial launch of the exVive3D ...
(Date:2/27/2015)... , Feb. 27, 2015  Uroplasty, Inc. (NASDAQ: ... manufactures and markets innovative proprietary products to treat voiding ... 27th Annual ROTH Conference on Tuesday, March 10, 2015. ... Brett Reynolds , Chief Financial Officer, will present at ... on one at the conference at the Ritz Carlton ...
(Date:2/27/2015)... JERUSALEM , Feb. 27, 2015  Chiasma, Inc., ... lead product for the orphan condition acromegaly, today announced ... round. Participants in the financing included new investors Rock ... chip public investment fund, as well as existing investors ... and ARCH Venture Partners. Chiasma intends ...
Breaking Medicine Technology:Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 2Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 3Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 4Uroplasty to Participate in the 27th Annual ROTH Conference 2Chiasma Announces Completion of $70 Million Series E Financing 2Chiasma Announces Completion of $70 Million Series E Financing 3
... ,SARAH, - a French national collaborative randomized controlled ... sorafenib in advanced hepatocellular carcinoma is now open ... a new randomized controlled trial to directly compare ... (SIR-Spheres ® microspheres; Sirtex Medical Limited, Australia) ...
... 2, 2012  On February 2, at the Late-Breaking Science Session ... the TREVO Study ( T hrombectomy ... O cclusions in acute ischemic stroke). This ... clot-removing stent retriever technology. Sixty patients were enrolled by seven ...
Cached Medicine Technology:New Study of Primary Liver Cancer Seeks to Enroll 400 French Patients 2New Study of Primary Liver Cancer Seeks to Enroll 400 French Patients 3New Study of Primary Liver Cancer Seeks to Enroll 400 French Patients 4Stryker Presents Results of the TREVO Prospective Clinical Study at the International Stroke Conference 2
(Date:2/28/2015)... In recent years Medical Marijuana has continuously ... as a way for them to expand their patient base ... medicine. Since the FDA still lists Cannabis as a Schedule ... licensed physicians that can help guide them when recommending ... in Santa Cruz, CA is a leader in the ...
(Date:2/28/2015)... With their commitment to achieving physical results and ... to their already robust library of oblique exercises. “Rope ... as, is often performed on a stationary piece of ... relatively safe manner and can be performed by individuals ... of “Rope Pulls” is located in the oblique exercises ...
(Date:2/28/2015)... 28, 2015 Mew and Company, a ... they now provide business consulting services in addition to ... tax planning and succession planning. Company finances are a ... professionals. On top of this, complex Canadian tax laws ... accounting. As a result, Mew and Company works to ...
(Date:2/28/2015)... For those people who are unable ... Mesothelioma Applied Research Foundation (Meso Foundation) will broadcast ... starting at 9:30 AM. , The live broadcast is ... can be accessed through any browser on a computer ... Symposium is a unique event that covers important treatment ...
(Date:2/28/2015)... Dr. Perry Patel , a ... recently announced a special offer for the Zoom!® Chairside ... for new and established patients at his Pismo Beach dentist office. ... white smile, Dr. Patel and his staff are offering ... from the regular price of $450. , Zoom! whitening ...
Breaking Medicine News(10 mins):Health News:Reputable Cannabis Doctor In Santa Cruz and Monterey Joins the Medical Cannabis Network 2Health News:Vancouver Corporate Tax Accountants Now Provide Business Consulting Services 2Health News:Mesothelioma Cancer Research Foundation Broadcasting Symposium Live 2Health News:Pismo Beach Dentist Announces Special for Zoom! Teeth Whitening 2
... , OCEANSIDE, Calif. , Feb. 4 ... International Association for Life Quality (IALQ) – a national ... quality life for those with developmental disabilities – announced ... available to underserved families with a child with autism ...
... , , XI,AN, China ... Inc. (OTC Bulletin Board: HFGB), a leading,developer and producer of ... and food production, today announced,preliminary 2009 results and provided guidance ... anticipates revenues between $13,million to $14 million for ...
... U.S.A. (Feb. 4, 2010) A novel finding, described today (Feb. ... from the National Cancer Institute, The University of Texas Health Science ... clue as to how genes can have what you might call ... but they can be cut and spliced to make different proteins, ...
... ... Easy” explains cloud computing technology and how it drives social change , ... Morgantown, WV (PRWEB) February 4, ... TeamHost ™ online platform for creating SaaS applications, has launched its new portal for ...
... using them or not, , THURSDAY, Feb. 4 (HealthDay ... (COPD) are often given inhaled corticosteroids to help ease ... these drugs may be of only limited benefit. , ... treat the symptoms of COPD, they have also been ...
... , NAPERVILLE, Ill. , Feb. ... the Illinois Supreme Court has struck down critically needed medical ... state and restoring predictability to our broken medical liability system. ... clear will of the people of Illinois who ...
Cached Medicine News:Health News:Scholarships Available for Special Needs Life Quality Plans 2Health News:Huifeng Bio-Pharmaceutical Provides Preliminary 2009 Financial Results and 2010 Guidance 2Health News:Huifeng Bio-Pharmaceutical Provides Preliminary 2009 Financial Results and 2010 Guidance 3Health News:Scientists ID a protein that splices and dices genes 2Health News:Virtual Global Launches Cloudipedia.com to Help Cloud Computing Newbies 2Health News:Virtual Global Launches Cloudipedia.com to Help Cloud Computing Newbies 3Health News:Steroids May Be Overrated in Treatment of COPD 2Health News:Steroids May Be Overrated in Treatment of COPD 3Health News:Statement From IHA President Maryjane A. Wurth on Illinois Supreme Court Medical Liability Ruling 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: